




Revista Colombiana de REUMATOLOGÍA

www.elsevier.es/rcreuma



Case report

Behçet's disease: A diagnostic challenge



María Paula Torres Ortiz*, Daniel Hernando Flórez Valencia,
Karen Sulay Rodríguez Díaz, Jairo Enrique López Aldana, Reynaldo Badillo Abril

Department of Internal Medicine, Hospital Universitario de Santander, Universidad Industrial de Santander, Bucaramanga, Colombia

ARTICLE INFO

Article history:

Received 14 September 2020

Accepted 30 December 2020

Available online 24 October 2022

Keywords:

Behçet's syndrome

Autoimmune diseases

Inflammation

Oral ulcers

ABSTRACT

Behçet's disease is a low prevalence disorder that is difficult to diagnose. Its forms of presentation are often confused with infectious processes that involve multiple treatments and prolonged hospital stays. This article presents the case of a 30-year-old man who consulted with non-specific symptoms that represented a diagnostic challenge for the medical team.

© 2021 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

Enfermedad de Behçet: un reto diagnóstico

RESUMEN

La enfermedad de Behçet es una patología de baja prevalencia y difícil diagnóstico, sus formas clínicas de presentación suelen confundirse con procesos infecciosos que implican múltiples tratamientos y estancias hospitalarias prolongadas. Este artículo presenta el caso de un hombre de 30 años quien consulta de manera repetitiva con síntomas inespecíficos, lo que representa un reto diagnóstico para el equipo médico.

© 2021 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Palabras clave:

Síndrome de Behçet

Enfermedades autoinmunes

Inflamación

Úlceras orales

Introduction

Behçet's disease is an autoinflammatory and autoimmune pathology difficult to diagnose^{1,2}; its clinical forms of presentation on the skin can be confused with pyogenic infectious

processes, which makes its diagnosis difficult and implies prolonged hospital stays with increased healthcare costs.

Case

A 30-year-old patient, with a progressive clinical picture of fever and sweating for 2 months, later with a dry cough, moderate pain in the testicles and lower back. Pyelonephritis was diagnosed in the initial care center by means of ultrasound studies and antibiotic management was started. During hos-

PII of original article: S0121-8123(21)00025-6

* Corresponding author.

E-mail address: mpaulat1197@gmail.com (M.P. Torres Ortiz).

2444-4405/© 2021 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.



Figure 1 – Lesions of the patient. A) Surface of the tongue with a rounded well-defined lesion covered by a yellowish pseudomembrane. B) Rounded ulcer with well-defined borders and a necrotic center, at the base of the penis. C) Pustular vesicles with erythematous halo, in the anterior thorax. D) Cicatricial lesion in the testicle after treatment.

pitalization, the patient presented an acneiform rash on the trunk and lower limbs, accompanied by painful ulcers on the penis, testicles, and mouth. Ten days later, the skin lesions improved and the patient was discharged with antibiotic treatment (dicloxacillin) and outpatient control.

Twenty-two days later, the patient consulted with the same symptoms, nocturnal fever, sweating, and testicular and lumbar pain. He was febrile, and ulcers in the testicles and oral mucosa, with pustular comedo-type lesions in the anterior chest in different stages of vesicular progression were discovered during the physical examination, without joint involvement (see Fig. 1).

Autoimmunity and microbiological studies were reported negative, blood and urine cultures did not isolate any microorganism; however, the acute phase reactants were elevated (see Table 1).

Given the difficulty of the case, the dermatology service was consulted in order to define the diagnosis and manage-

ment of the patient. Corticosteroids were administered during the hospital-stay and the fever improved 48 h later. The clinic and the subsequent pathology report were compatible with Behçet's disease. The patient was dewormed and treatment with prednisolone, colchicine and azathioprine was started.

Discussion

In individuals with a genetic predisposition, various exogenous genetic factors can trigger Behçet's disease. Studies demonstrate that the presence of the HLA-B51 allele of chromosome 6p is higher in these patients, while variants of interleukin (IL) 10 and IL-37 have a reduced expression.³ The relationship with infectious agents is based on a cross-reaction by molecular mimicry with the participation of the innate immune system.^{3,4}

Table 1 – Laboratory studies.

Test	Result
<i>Autoimmunity studies</i>	
Complement	Negative
Rheumatoid factor	Negative
Antinuclear antibodies (ANAS)	Negative
<i>Microbiological studies</i>	
Blood count	Without alterations
Thick blood smear	Negative
VDRL	Negative
HIV	Negative
Hepatotropic viruses	Negative
Mycobacterium	Negative
Herpes virus	Negative
Cytomegalovirus	Negative
Epstein-Barr	Negative
Blood cultures	Negative
Urine culture	Negative
<i>Acute phase reactants</i>	
CRP	159.50 mg/dl (0–5 mg/dl)
ESR	111 mL/h (5–20 mL/h)
Ferritin	1920.8 ng/mL (30–400 ng/mL)

Oral ulcers are the first sign of the disease in 80% of cases. These have well-defined borders, with an erythematous halo, are painful, and can leave sequelae such as scars, dysphagia, odynophagia, and dyspnea.⁵ Genital lesions are another important manifestation of the disease.

Ocular manifestations mainly affect the retina and the uvea in 30–70% of cases and can appear up to 3 years after the onset of symptoms. Only 20% of the cases begin with ocular involvement, which did not occur in our patient. The follow-up of these subjects is very important to avoid sequelae in visual acuity. Neurological involvement occurs in 10% of the patients, especially in men, and can appear up to 5 years after onset, as well as joint manifestations, which can occur in up to 60% of patients, affecting the knees, ankles and wrists.⁶

Currently, the diagnosis of this disease is clinical, based on the New International Criteria for Behçet's Disease (ICBD). A score higher than 4 is required to confirm the diagnosis. These criteria include skin lesions, oral and genital aphthae, among others. Histopathologic studies are nonspecific but may show perivascular inflammatory infiltrates with associated fibrinoid necrosis.⁷

The management of the disease varies depending on the compromise of the affected system; colchicine is a first line agent in mucocutaneous involvement. The phosphodiesterase 4 inhibitor, apremilast, and the interleukin-1 receptor antagonist anakinra are effective options for refractory mucocutaneous involvement.⁸

A case-control study found a significant association between multidimensional fatigue, anxiety, depression, and physical dysfunction; therefore, these symptoms are important to accomplish a diagnostic approach.⁹

Conclusion

It is essential to identify Behçet's disease in the services, since due to its difficult diagnosis it can be confused with other

pathologies of infectious origin, which implies the unnecessary use of multiple treatments and affects the quality of life of patients.

Ethical Considerations

For the study and publication of the case, prior written informed consent was obtained from the patient. The photographs presented here preserve the patient's identity and do not show characters that would facilitate their identification. This is to protect their rights and confidentiality.

Funding

This work has not received specific aids from public sector agencies, the commercial sector or non-profit entities.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgment

We thank the patient, who allowed us to know his case, review it and learn from it.

REFERENCES

1. Davatchi F. Behçet's disease. *Int J Rheum Dis*. 2014;17:355–7, <http://dx.doi.org/10.1111/1756-185X.12378>.
2. Hedayatfar A. Behçet's disease: Autoimmune or autoinflammatory? *J Ophthalmic Vis Res*. 2013;8:291–3.
3. Tong B, Liu X, Xiao J, Su G. Immunopatogénesis de la enfermedad de Behçet. *Front Immunol*. 2019;10:665, <http://dx.doi.org/10.3389/fimmu.2019.00665>.
4. Pay S, Simşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. *Rheumatol Int*. 2007;27:417–24, <http://dx.doi.org/10.1007/s00296-006-0281-6>.
5. Scherrer MAR, Rocha VB, Garcia LC. Behçet's disease: Review with emphasis on dermatological aspects. *An Bras Dermatol*. 2017;92:452–64, <http://dx.doi.org/10.1590/abd1806-4841.20177359>.
6. Bulur I, Onder M. Behçet disease: New aspects. *Clin Dermatol*. 2017;35:421–34, <http://dx.doi.org/10.1016/j.clindermatol.2017.06.004>.
7. Molina RA, Huerta-Rosario A, Alva Díaz CA, Mejía Rojas KK, Mori N, Romero Sánchez R. Neuro-Behçet's disease in Peru: A case report and literature review. *Medwave*. 2017;17:e6978, <http://dx.doi.org/10.5867/medwave.2017.05.6978>.
8. Alibaz-Oner F, Sawalha AH, Direskeneli H. Management of Behçet's disease. *Curr Opin Rheumatol*. 2018;30:238–42, <http://dx.doi.org/10.1097/BOR.0000000000000497>.
9. İlhan B, Can M, Alibaz-Oner F, Yılmaz-Oner S, Polat-Korkmaz O, Ozen G, et al. Fatigue in patients with Behçet's syndrome: Relationship with quality of life, depression, anxiety, disability and disease activity. *Int J Rheum Dis*. 2018;21:2139–45, <http://dx.doi.org/10.1111/1756-185X.12839>.